<DOC>
	<DOCNO>NCT00433862</DOCNO>
	<brief_summary>The three main chronic myeloproliferative disorder polycythemia vera ( PV ) , essential thrombocythemia ( ET ) idiopathic myelofibrosis ( IMF ) . These clonal neoplastic disease characterize proliferation one hematopoietic lineage . Recently mutation Janus Kinase 2 ( JAK2 ) gene lead substitution phenylalanine valine position 617 JAK2 protein , JAK2 V617F , find 76 % 97 % patient PV , 29 % 57 % patient ET 50 % patient IMF . This mutation confers constitutive activity JAK2 protein appear play important role pathobiology condition . However , patient myeloproliferative disorder mutation may primary cause disease . The primary goal prospective natural history study investigate molecular basis disease group patient JAK2 V617F . A second goal identify biomarkers PV myeloproliferative disorder easier measure JAK2 V617F . Approximately , 150 patient myeloproliferative disorder study 3 year . The study involve collection 40 mL 50 mL peripheral blood subject . The blood use assess neutrophil gene protein expression , gene polymorphism , plasma protein level .</brief_summary>
	<brief_title>Molecular Changes Biomarkers Chronic Myeloproliferative Disorders</brief_title>
	<detailed_description>The three main chronic myeloproliferative disorder polycythemia vera ( PV ) , essential thrombocythemia ( ET ) idiopathic myelofibrosis ( IMF ) . These clonal neoplastic disease characterize proliferation one hematopoietic lineage . Recently mutation Janus Kinase 2 ( JAK2 ) gene lead substitution phenylalanine valine position 617 JAK2 protein , JAK2 V617F , find 76 % 97 % patient PV , 29 % 57 % patient ET 50 % patient IMF . This mutation confers constitutive activity JAK2 protein appear play important role pathobiology condition . However , patient myeloproliferative disorder mutation may primary cause disease . The primary goal prospective natural history study investigate molecular basis disease group patient JAK2 V617F . A second goal identify biomarkers PV myeloproliferative disorder easier measure JAK2 V617F . Approximately , 150 patient myeloproliferative disorder study 3 year . The study involve collection 40 mL 50 mL peripheral blood subject . The blood use assess neutrophil gene protein expression , gene polymorphism , plasma protein level .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Diagnosis suspect diagnosis PV , ET , IMF . The World Health Organization Criteria use diagnose disorder . In brief , criterion PV hemoglobin great 18.5 g/dL men great 16.5 g/dL woman splenomegaly palpation absence secondary erythrocytosis . If splenomegaly absent , patient must 2 follow 4 minor criterion : platelet count great 400 x 10 ( 9 ) /L , leukocyte count great 12 x 10 ( 9 ) /L , marrow biopsy trilineage increase cellularity , low serum erythropoietin level . The criterion EF platelet count great 600 x 10 ( 9 ) /L know cause reactive thrombocytosis normal hemoglobin . The criterion IMF fibrosis bone marrow splenomegaly without precede PV , ET chronic myelogenous leukemia . 2 . Both male female subject study . 3 . Any ethnic group . 4 . 18 year age old . EXCLUSION CRITERIA : Subjects exclude follow condition : 1 . Increased blood count due disease chronic myeloproliferation . 2 . Know history anemia ( hematocrit le 12.0 mg/dL ) . 3 . Pregnancy . 4 . Infection HIV , hepatitis B , hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 19, 2010</verification_date>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Essential Thrombocytosis</keyword>
	<keyword>Idiopathic Myelofibrosis</keyword>
	<keyword>Janus Kinase 2</keyword>
	<keyword>CD177</keyword>
	<keyword>Chronic Myeloproliferative Disorders</keyword>
	<keyword>PV</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>ET</keyword>
	<keyword>IM</keyword>
</DOC>